Zenas BioPharma, Inc. Common Stock

ZBIO XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

1.1B

Short interest (May 15)

16.9%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.75%

↑ 2.2%

Available Shares

200K

↓ 17.1%

Price Chart

Company Overview

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001953926

Asset Type: CS

Market Data

Market Cap: $1,081,474,748

Employees: 167

Status: Active

Short Interest

Current Borrow Fee 0.75%

Range: 0.68% - 0.75%

Available Shares 200K

Range: 150K - 150K

Recent Changes

Fee Change: ↑ 4.4%

Available Change: ↑ 117.4%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime